Bottom line
CHNA vs XLV: the short answer
CHNA (Loncar China BioPharma ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs.
Updated Nov 19, 2026
CHNA vs XLV side by side
| CHNA | XLV | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Grayscale | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | — | 0.08% |
| Annual cost per $10k | — | $8 |
| 10-yr cost on $10k (prospectus) | — | $103 |
| Max front load | None | None |
| 12b-1 fee | — | 0.02% |
| 1-yr return | — | +14.5% |
| 5-yr return (annualized) | — | +8.1% |
| 10-yr return (annualized) | — | +9.8% |
| Best quarter | — | +14.5% |
| Worst quarter | — | −12.7% |
| Net assets (fund) | — | $40.6B |
| Number of holdings | — | 65 |
| Portfolio turnover | — | 2% |
| Returns as of | — | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
CHNA and XLV share none of their top holdings.
CHNA top 10
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between CHNA and XLV?
CHNA (Loncar China BioPharma ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs.
Should I own both CHNA and XLV?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.